Abstract
At present, cancer accounts for 12% of the 56 million deaths occurring annually, making it one of the leading causes for death. The primary obstacle clinicians face today is that they are not adequately equipped to tackle this imminent threat. However, with the recent developments in the field of oncogenomics, our knowledge of exactly where, why and how tumorigenesis occurs has increased manifold. Genomic technologies such as 'comparative genomic hybridization' and cDNA microarrays have helped to improve our understanding of the genetic basis of cancer. Researchers are presently looking towards developing new anticancer drugs based on the discovery of novel molecular targets. The success stories of agents like Trastuzumab and GleevecAE)used in the therapy of HER-2 positive breast cancers and chronic myelegenous leukemia (CML) respectively, give us hope that not too long from now, oncogenomics will no longer remain a mere research modality, but will be used in clinical practice for the effective therapy of cancer. This article reviews some of the more recent developments in the field of cancer genomics and discusses the current status as well as the future trends.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
